Shopping Cart 0
Cart Subtotal
USD 0

Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA300/301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of its drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Immatics Biotech Raises USD58 Million in Series E Financing 10

immatics biotech Raises Additional USD29.8 Million in Second Tranche of Series D Financing 11

Partnerships 12

MorphoSys Enters into Agreement with Immatics Biotech 12

Licensing Agreements 13

Genmab Enters into Licensing Agreement with Immatics Biotechnologies 13

Roche Exercises Option for Licensing Agreement with Immatics 14

Amgen Enters into Licensing Agreement with Immatics Biotech 15

Immatics Biotech Enters into Licensing Agreement with Sanquin Blood Supply Foundation 16

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 17

Equity Offering 18

Immatics US Raises USD10 Million in Financing 18

Immatics Biotechnologies GmbH-Key Competitors 19

Immatics Biotechnologies GmbH-Key Employees 20

Immatics Biotechnologies GmbH-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Joint Venture 21

Recent Developments 22

Corporate Communications 22

May 14, 2018: Immatics Appoints Stephen Eck as Chief Medical Officer US 22

Jan 17, 2018: Immatics Appoints Thomas Ulmer as CFO 23

Appendix 24

Methodology 24

About GlobalData 24

Contact Us 24

Disclaimer 24


List Of Figure

List of Figures

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Immatics Biotechnologies GmbH, Deals By Therapy Area, 2012 to YTD 2018 8

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Immatics Biotech Raises USD58 Million in Series E Financing 10

immatics biotech Raises Additional USD29.8 Million in Second Tranche of Series D Financing 11

MorphoSys Enters into Agreement with Immatics Biotech 12

Genmab Enters into Licensing Agreement with Immatics Biotechnologies 13

Roche Exercises Option for Licensing Agreement with Immatics 14

Amgen Enters into Licensing Agreement with Immatics Biotech 15

Immatics Biotech Enters into Licensing Agreement with Sanquin Blood Supply Foundation 16

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 17

Immatics US Raises USD10 Million in Financing 18

Immatics Biotechnologies GmbH, Key Competitors 19

Immatics Biotechnologies GmbH, Key Employees 20

Immatics Biotechnologies GmbH, Other Locations 21

Immatics Biotechnologies GmbH, Joint Venture 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA300/301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of its drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Immatics Biotech Raises USD58 Million in Series E Financing 10

immatics biotech Raises Additional USD29.8 Million in Second Tranche of Series D Financing 11

Partnerships 12

MorphoSys Enters into Agreement with Immatics Biotech 12

Licensing Agreements 13

Genmab Enters into Licensing Agreement with Immatics Biotechnologies 13

Roche Exercises Option for Licensing Agreement with Immatics 14

Amgen Enters into Licensing Agreement with Immatics Biotech 15

Immatics Biotech Enters into Licensing Agreement with Sanquin Blood Supply Foundation 16

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 17

Equity Offering 18

Immatics US Raises USD10 Million in Financing 18

Immatics Biotechnologies GmbH-Key Competitors 19

Immatics Biotechnologies GmbH-Key Employees 20

Immatics Biotechnologies GmbH-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Joint Venture 21

Recent Developments 22

Corporate Communications 22

May 14, 2018: Immatics Appoints Stephen Eck as Chief Medical Officer US 22

Jan 17, 2018: Immatics Appoints Thomas Ulmer as CFO 23

Appendix 24

Methodology 24

About GlobalData 24

Contact Us 24

Disclaimer 24


List Of Figure

List of Figures

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Immatics Biotechnologies GmbH, Deals By Therapy Area, 2012 to YTD 2018 8

Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Immatics Biotech Raises USD58 Million in Series E Financing 10

immatics biotech Raises Additional USD29.8 Million in Second Tranche of Series D Financing 11

MorphoSys Enters into Agreement with Immatics Biotech 12

Genmab Enters into Licensing Agreement with Immatics Biotechnologies 13

Roche Exercises Option for Licensing Agreement with Immatics 14

Amgen Enters into Licensing Agreement with Immatics Biotech 15

Immatics Biotech Enters into Licensing Agreement with Sanquin Blood Supply Foundation 16

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 17

Immatics US Raises USD10 Million in Financing 18

Immatics Biotechnologies GmbH, Key Competitors 19

Immatics Biotechnologies GmbH, Key Employees 20

Immatics Biotechnologies GmbH, Other Locations 21

Immatics Biotechnologies GmbH, Joint Venture 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS